Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 9/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | GAA | P10253 | 5/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | BCAT1 | P54687 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25284025 | 0.91 | KAT6A (0.65) | KAT6AMEN1KMT2AGAAHTT | |
| SCHEMBL4765513 | 0.88 | KAT6A (1.00) | KAT6AMEN1KMT2AGAAHTT | |
| SCHEMBL25241197 | 0.87 | KMT2A (0.71) | KAT6AMEN1KMT2AGAAHTT | |
| SCHEMBL26104327 | 0.87 | MEN1 (1.00) | KAT6AMEN1KMT2AGAAHTT | |
| SCHEMBL25872128 | 0.86 | KAT6A (0.60) | KAT6AMEN1KMT2AGAAHTT | |
| SCHEMBL6400145 | 0.85 | KAT6A (0.81) | KAT6AMEN1KMT2AGAAHTT | |
| SCHEMBL20233293 | 0.84 | KAT6A (0.78) | KAT6AMEN1KMT2AGAAHTT | |
| SCHEMBL20233361 | 0.84 | KAT6A (0.78) | KAT6AMEN1KMT2AGAAHTT | |
| SCHEMBL8660071 | 0.83 | MEN1 (0.87) | KAT6AMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL25289667 | 0.82 | KAT6A (0.82) | KAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014841-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | HU LAIN-YEN (US) | 2005-01-20 | — | — | US | disclosed |
| US-6809119-B2 | FOR USE AS AS NEURO-PROTECTIVE AGENTS FOR THERAPY OF CONDITIONS SUCH AS STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMINOGLYCOSIDE ANTIBIOTICS-INDUCED HEARING LOSS, MIGRAINE | WARNER-LAMBERT COMPANY LLC | 2004-10-26 | — | — | US | disclosed |
| US-20030149110-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | HU LAIN-YEN (US) | 2003-08-07 | — | — | US | disclosed |
| WO-2003045902-A1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2003-06-05 | — | — | WO | disclosed |
| EP-1314723-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149110-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | KAT6A 1643/4885MEN1 2643/4885KMT2A 646/4885 |
| US-20050014841-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | KAT6A 1643/4885MEN1 2643/4885KMT2A 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.